Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | DHODH | Q02127 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13073510 | 0.86 | HTR2A (0.43) | HPGDALOX15LMNATP53CYP3A4 | |
| SCHEMBL10183552 | 0.86 | PDE2A (0.44) | HPGDALOX15LMNATP53CYP3A4 | |
| SCHEMBL28857734 | 0.84 | CA1 (0.44) | HPGDALOX15LMNACYP3A4CA1 | |
| SCHEMBL20441362 | 0.84 | CNR2 (0.43) | HPGDALOX15LMNATP53CYP3A4 | |
| SCHEMBL19318453 | 0.84 | CYP3A4 (0.43) | HPGDALOX15LMNATP53CYP3A4 | |
| SCHEMBL19323005 | 0.84 | CNR2 (0.41) | HPGDALOX15LMNATP53CYP3A4 | |
| SCHEMBL12894420 | 0.83 | SMN1; SMN2 (0.38) | HPGDALOX15LMNATP53CYP3A4 | |
| SCHEMBL26780223 | 0.83 | LMNA (0.42) | HPGDALOX15LMNATP53CYP3A4 | |
| SCHEMBL1535615 | 0.83 | HPGD (0.48) | HPGDALOX15LMNATP53CYP3A4 | |
| SCHEMBL179467 | 0.82 | CA2 (0.50) | HPGDALOX15CYP3A4CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110323380-A | A kind of float type fire-type ferric phosphate lithium cell group system and its charging method | 上海航天电源技术有限责任公司 | 2019-10-11 | — | — | CN | claimed |
| EP-1733450-B1 | REDOX SHUTTLE FOR RECHARGEABLE LITHIUM-ION CELL | 3M INNOVATIVE PROPERTIES CO (US) | 2010-12-08 | — | — | EP | claimed |
| US-7811710-B2 | Redox shuttle for rechargeable lithium-ion cell | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2010-10-12 | — | — | US | claimed |
| US-20050221196-A1 | Redox shuttle for rechargeable lithium-ion cell | 3M INNOVATIVE PROPERTIES COMPANY | 2005-10-06 | — | — | US | claimed |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-01-25 | — | — | US | disclosed |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-01-25 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-7648801-B2 | Lithium battery with series-connected cells having a shuttle of 2,5-di-tert--butyl-1,4-dimethoxybenzene; limits the negative electrode potential to a value slightly above that of positive electrode maximum normal operating potential toprevent negative electrode from reaching a higher damaging one | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2010-01-19 | — | — | US | disclosed |
| US-20090082330-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090062213-A1 | Small Molecule Inhibitors of PDZ Interactions | ARBOR VITA CORPORATION (US) | 2009-03-05 | — | — | US | disclosed |
| US-20080227684-A1 | Small Molecule Inhibitors of PDZ Interactions | NONO INC. (CA) | 2008-09-18 | — | — | US | disclosed |
| CN-1720287-A | Monosubstituted 6-aminouracils for the stabilisation of halogenated polymers | CROMPTON VINYL ADDITIVES GMBH (DE) | 2006-01-11 | — | — | CN | disclosed |
| US-20050221168-A1 | Redox shuttle for overdischarge protection in rechargeable lithium-ion batteries | DAHN JEFFREY R | 2005-10-06 | — | — | US | disclosed |
| US-20050221196-A1 | Redox shuttle for rechargeable lithium-ion cell | 3M INNOVATIVE PROPERTIES COMPANY | 2005-10-06 | — | — | US | disclosed |
| CN-1111657-A | Stabilized polyvinly chloride | CIBA GEIGY AG (CH) | 1995-11-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | HPGD 2492/4885ALOX15 4811/4885LMNA 4415/4885 |
| US-20090062213-A1 | Small Molecule Inhibitors of PDZ Interactions | PDLIM5, DAB2IP, PSD | HPGD 3838/4885ALOX15 4652/4885LMNA 4338/4885 |
| US-11713321-B2 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | HPGD 2524/4885ALOX15 3803/4885LMNA 373/4885 |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | HPGD 1303/4885ALOX15 3378/4885LMNA 334/4885 |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | EGFR, ERBB2, CBL | HPGD 3988/4885ALOX15 4759/4885LMNA 3971/4885 |
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | USP1, USP8, USP7 | HPGD 3731/4885ALOX15 4808/4885LMNA 2679/4885 |
| US-20090082330-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, MYD88 | HPGD 1470/4885ALOX15 521/4885LMNA 4162/4885 |
| US-20080227684-A1 | Small Molecule Inhibitors of PDZ Interactions | PDLIM5, DAB2IP, PSD | HPGD 3838/4885ALOX15 4652/4885LMNA 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.